Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV in routine clinical practice in Turkiye: 12-month outcomes from the KLIMIK HIV-TR cohort.
A once-daily HIV combination pill works well in real patients, confirming clinical trial benefits across diverse populations.
BIC/FTC/TAF shows high effectiveness and good tolerability in real-world Turkish HIV patients at 12 months, consistent with clinical trial data. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective cohort (12-month national registry)
- Category
- sentinel
- Maturity
- Validated
- Journal
- AIDS Res Ther
Why it surfaced
Sentinel-flagged real-world validation study for an established HIV regimen; limited novelty but relevant for Phase 3/RCT external validation monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.